Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024
WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of...
Cancer
BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order
VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced...
ASCCP Releases Innovative ‘Enduring Guidelines’ to Combat Cervical Cancer
CLARKSBURG, MD / ACCESSWIRE / March 7, 2024 / The American Society for Colposcopy and Cervical Pathology (ASCCP) is proud...
eHealth Technologies Expedites Time to Treatment for Patients by Integrating AI
PITTSBURGH, March 7, 2024 /PRNewswire/ -- eHealth Technologies, a trailblazer in healthcare technology solutions for close to 20 years, has...
Verismo Therapeutics Announces Opening of Second Clinical Site for STAR-101 Phase 1 Trial
Clinical-stage CAR-T company is actively recruiting patients to evaluate SynKIR™-110, a new treatment candidate for ovarian cancer, mesothelioma, and cholangiocarcinoma...
Evogene Reports Fourth Quarter and Full Year 2023 Financial Results
Conference call and webcast: today, March 7, 2024, 9:00 am E.T. +1-888-407-2553 or +972-3- 9180608 I https://veidan.activetrail.biz/evogeneq4-2023 REHOVOT, Israel, March...
Nabsys Opens a Distribution Channel for the OhmX™ Platform in Canada
PROVIDENCE, R.I., March 7, 2024 /PRNewswire/ -- Next generation genomic tools company, Nabsys®, has executed a nonexclusive agreement with Canadian distributor,...
MEDITECH to Spotlight Intelligent Interoperability at HIMSS24
API advancements and new technology partnerships will be highlighted in MEDITECH Interoperability Showcase Kiosk #71CANTON, Mass.--(BUSINESS WIRE)--As the healthcare industry...
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
Initial interim data show favorable drug exposure and confirm ALG.APV-527 biological activityEarly promising signs of clinical activity in heavily pretreated...
Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing
NORTHAMPTON, MA / ACCESSWIRE / March 7, 2024 / Gilead SciencesFor many people living with cancer, hearing about the experiences...
Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial...
AIM ImmunoTech Announces Launch of CEO Corner Platform
AIM CEO Corner AIM CEO Corner CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline...
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...
TOMI Expands SteraMist iHP Corporate Service Contracts and Clients
Company announces new partners including The University of Texas and Rising Pharmaceuticals FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) --...
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy
Data support evaluation of the effects of two weeks of TNX-102 SL therapy on severity of acute stress reaction (ASR)...
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer),...
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug...
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System
Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high...
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income...